ArriVent BioPharma, Inc. Common Stock (AVBP) is a Healthcare · Biotechnology company listed on NASDAQ. Price $29.02 (+2.33%), Market cap $1.30B, 52-week low–high $16.95 ~ $31.39.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-hel
Financial statements, price targets, institutional (13F) holdings and related news for ArriVent BioPharma, Inc. Common Stock are updated in real time on BlackAll Trade.
ArriVent BioPharma, Inc. Common Stock trades at $29.02 (+2.33%). Real-time quotes and charts are available on BlackAll Trade.
ArriVent BioPharma, Inc. Common Stock has a market cap of about $1.30B.
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancer